雅培在2025年第一季度发布了强劲的财报,实现营收103.6亿美元,同比增长4.0%。若剔除汇率和业务退出影响,有机增长达6.9%,进一步剔除新冠相关收入后,有机增长高达8.3%。各业务板块表现亮眼:医疗器械收入48.95亿美元,同比增长9.9%;营养业务收入21.46亿美元,同比增长3.8%;仿制药业务收入12.6亿美元,同比增长2.7%;诊断业务受新冠检测需求下降影响,同比下降7.2%,但排除...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.